eligibility_summary
Adults 18–75 with advanced, unresectable, GPC3+ HCC after ≥2 systemic lines, measurable disease, ECOG 0–1, Child‑Pugh A/B7, adequate organ function, controlled HBV allowed. Key exclusions: allergy, CNS disease, major cardio‑pulmonary disease, prior CAR‑T/anti‑GPC3, liver tumor burden >70% or main portal vein thrombosis, active serious infection (incl HIV/HCV/HBV+HDV/syphilis), therapeutic anticoagulation/bleeding risk, pregnancy/lactation, major surgery, unresolved ≥G2 AEs.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT06590246 tests C-CAR031, an “armored,” GPC3-targeted autologous CAR T-cell therapy (biological, gene-modified cell therapy) for advanced/recurrent GPC3+ hepatocellular carcinoma. Mechanism: patient T cells are engineered to express a chimeric antigen receptor that binds glypican‑3 on tumor cells, triggering T‑cell activation, cytokine release, and direct cytotoxic killing of GPC3+ cells. The “armored” design is intended to enhance T‑cell persistence/function within the solid-tumor microenvironment. Targets: tumor cells expressing glypican‑3, immune pathway activation via CAR signaling in T cells and modulation of the immunosuppressive tumor microenvironment. Single IV infusion, Phase I/II.